131 related articles for article (PubMed ID: 27352563)
1. An economic analysis of cisplatin alone versus cisplatin doublets in the treatment of women with advanced or recurrent cervical cancer.
McKim A; Walter AC; Sheely KM; Manahan KJ; Geisler JP
Eur J Gynaecol Oncol; 2016; 37(3):353-6. PubMed ID: 27352563
[TBL] [Abstract][Full Text] [Related]
2. Topotecan for the treatment of recurrent and stage IVB carcinoma of the cervix.
Paton F; Paulden M; Saramago P; Manca A; Misso K; Palmer S; Eastwood A
Health Technol Assess; 2010 May; 14 Suppl 1():55-62. PubMed ID: 20507804
[TBL] [Abstract][Full Text] [Related]
3. Health-related quality of life outcomes associated with four cisplatin-based doublet chemotherapy regimens for stage IVB recurrent or persistent cervical cancer: a Gynecologic Oncology Group study.
Cella D; Huang HQ; Monk BJ; Wenzel L; Benda J; McMeekin DS; Cohn D; Ramondetta L; Boardman CH
Gynecol Oncol; 2010 Dec; 119(3):531-7. PubMed ID: 20837359
[TBL] [Abstract][Full Text] [Related]
4. Treatment of advanced or recurrent cervical cancer with Cisplatin or Cisplatin containing regimens: a cost effective analysis.
Geisler JP; Swathirajan J; Wood KL; Manahan KJ
J Cancer; 2012; 3():454-8. PubMed ID: 23236342
[TBL] [Abstract][Full Text] [Related]
5. Systematic Review and Network Meta-Analysis of Bevacizumab Plus First-Line Topotecan-Paclitaxel or Cisplatin-Paclitaxel Versus Non-Bevacizumab-Containing Therapies in Persistent, Recurrent, or Metastatic Cervical Cancer.
Rosen VM; Guerra I; McCormack M; Nogueira-Rodrigues A; Sasse A; Munk VC; Shang A
Int J Gynecol Cancer; 2017 Jul; 27(6):1237-1246. PubMed ID: 28448304
[TBL] [Abstract][Full Text] [Related]
6. Topotecan, pegylated liposomal doxorubicin hydrochloride and paclitaxel for second-line or subsequent treatment of advanced ovarian cancer: a systematic review and economic evaluation.
Main C; Bojke L; Griffin S; Norman G; Barbieri M; Mather L; Stark D; Palmer S; Riemsma R
Health Technol Assess; 2006 Mar; 10(9):1-132. iii-iv. PubMed ID: 16545208
[TBL] [Abstract][Full Text] [Related]
7. Bevacizumab for advanced cervical cancer: patient-reported outcomes of a randomised, phase 3 trial (NRG Oncology-Gynecologic Oncology Group protocol 240).
Penson RT; Huang HQ; Wenzel LB; Monk BJ; Stockman S; Long HJ; Ramondetta LM; Landrum LM; Oaknin A; Reid TJ; Leitao MM; Method M; Michael H; Tewari KS
Lancet Oncol; 2015 Mar; 16(3):301-11. PubMed ID: 25638326
[TBL] [Abstract][Full Text] [Related]
8. Medical therapy of advanced malignant epithelial tumours of the ovary.
Colombo N; Parma G; Bocciolone L; Franchi D; Sideri M; Maggioni A
Forum (Genova); 2000; 10(4):323-32. PubMed ID: 11535983
[TBL] [Abstract][Full Text] [Related]
9. A randomized phase III trial of platinum chemotherapy plus paclitaxel with bevacizumab and atezolizumab versus platinum chemotherapy plus paclitaxel and bevacizumab in metastatic (stage IVB), persistent, or recurrent carcinoma of the cervix: the BEATcc study (ENGOT-Cx10/GEICO 68-C/JGOG1084/GOG-3030).
Grau JF; Farinas-Madrid L; Oaknin A
Int J Gynecol Cancer; 2020 Jan; 30(1):139-143. PubMed ID: 31645423
[TBL] [Abstract][Full Text] [Related]
10. Topotecan in cervical cancer.
Ackermann S; Beckmann MW; Thiel F; Bogenrieder T
Int J Gynecol Cancer; 2007; 17(6):1215-23. PubMed ID: 17997795
[TBL] [Abstract][Full Text] [Related]
11. Final survival analysis of topotecan and paclitaxel for first-line treatment of advanced cervical cancer: An NRG oncology randomized study.
Tewari KS; Sill MW; Birrer MJ; Penson RT; Huang H; Moore DH; Ramondetta LM; Landrum LM; Oaknin A; Reid TJ; Leitao MM; Michael HE; Monk BJ
Gynecol Oncol; 2023 Apr; 171():141-150. PubMed ID: 36898292
[TBL] [Abstract][Full Text] [Related]
12. Chemotherapy for advanced, recurrent, and metastatic cervical cancer.
Moore DH
J Natl Compr Canc Netw; 2008 Jan; 6(1):53-7. PubMed ID: 18267059
[TBL] [Abstract][Full Text] [Related]
13. The rationale for the use of non-platinum chemotherapy doublets for metastatic and recurrent cervical carcinoma.
Tewari KS; Monk BJ
Clin Adv Hematol Oncol; 2010 Feb; 8(2):108-15. PubMed ID: 20386532
[TBL] [Abstract][Full Text] [Related]
14. Chemotherapy for recurrent cervical cancer.
Pectasides D; Kamposioras K; Papaxoinis G; Pectasides E
Cancer Treat Rev; 2008 Nov; 34(7):603-13. PubMed ID: 18657909
[TBL] [Abstract][Full Text] [Related]
15. Recent achievements and future developments in advanced and recurrent cervical cancer: trials of the Gynecologic Oncology Group.
Tewari KS; Monk BJ
Semin Oncol; 2009 Apr; 36(2):170-80. PubMed ID: 19332251
[TBL] [Abstract][Full Text] [Related]
16. Management of patients with recurrent/advanced cervical cancer beyond first line platinum regimens: Where do we stand? A literature review.
Boussios S; Seraj E; Zarkavelis G; Petrakis D; Kollas A; Kafantari A; Assi A; Tatsi K; Pavlidis N; Pentheroudakis G
Crit Rev Oncol Hematol; 2016 Dec; 108():164-174. PubMed ID: 27931835
[TBL] [Abstract][Full Text] [Related]
17. Gynecologic oncology group trials of chemotherapy for metastatic and recurrent cervical cancer.
Tewari KS; Monk BJ
Curr Oncol Rep; 2005 Nov; 7(6):419-34. PubMed ID: 16221379
[TBL] [Abstract][Full Text] [Related]
18. Prognostic factors from a randomized phase III trial of paclitaxel and carboplatin versus paclitaxel and cisplatin in metastatic or recurrent cervical cancer: Japan Clinical Oncology Group (JCOG) trial: JCOG0505-S1.
Nishio S; Kitagawa R; Shibata T; Yoshikawa H; Konishi I; Ushijima K; Kamura T
Cancer Chemother Pharmacol; 2016 Oct; 78(4):785-90. PubMed ID: 27553435
[TBL] [Abstract][Full Text] [Related]
19. Quality of life (QOL) outcomes from a randomized trial of cisplatin versus cisplatin plus paclitaxel in advanced cervical cancer: a Gynecologic Oncology Group study.
McQuellon RP; Thaler HT; Cella D; Moore DH
Gynecol Oncol; 2006 May; 101(2):296-304. PubMed ID: 16376417
[TBL] [Abstract][Full Text] [Related]
20. Chemotherapy for recurrent cervical cancer.
Cadron I; Van Gorp T; Amant F; Leunen K; Neven P; Vergote I
Gynecol Oncol; 2007 Oct; 107(1 Suppl 1):S113-8. PubMed ID: 17804044
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
